This site is intended for US healthcare professionals

Congresses

The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

World Sleep
October 20th – 25th 2023, Rio de Janeiro, Brazil
Explore materials from this congress
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted.
Narcolepsy
PRESENTATION
Preliminary Results from a Phase 1 Study of ALKS 2680, an Orexin 2 Receptor Agonist, in Healthy Participants and Patients with Narcolepsy or Idiopathic Hypersomnia
AUTHOR(S)

Brendon Yee,1 Julia Chapman,1 Ron Grunstein,1 Christopher Argent,2 Angela D’Rozario,1 Craig Hopkinson,3 Jandira Ramos,3 Ishani Landry,3 Sergey Yagoda,3 Bhaskar Rege3

Narcolepsy
PRESENTATION
Evaluation of a Novel, Orally Available Orexin 2 Receptor Agonist on Wakefulness and Cataplexy in a Mouse Model of Narcolepsy Type 1
AUTHOR(S)

Julie Brooks,1 Yu Sun,2 Tom Kilduff,2 Laura Tan,1 Brian Raymer1

Narcolepsy
POSTER
Diagnosis and Symptoms of Narcolepsy From the Patient Perspective: Results From In-Depth Qualitative Interviews
AUTHOR(S)

Michael J. Doane,1 Meaghan O’Connor,2 Miranda Lauher-Charest,2 Laura Tesler Waldman,2 Bhaskar Rege,1 Wilbur P. Williams, III1